Skip to search formSkip to main contentSkip to account menu

continuous erythropoietin receptor activator

Known as: CERA (erythropoietin receptor activator) 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

ErythropoietinPolyethylene Glycols
Methoxy polyethylene glycol-epoetin betaRo 50-3821

Narrower (1)

Mircera

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Hepcidin in neoplastic disease
Abnormalities in iron metabolism are frequent in the neoplastic disease. The relationship between hepcidin and iron homeostasis… 
Highly Cited
2012
Highly Cited
2012
Effects of Continuous Erythropoietin Receptor Activator in Sepsis-Induced Acute Kidney Injury and Multi-Organ Dysfunction
Background Despite advances in supportive care, sepsis-related mortality remains high, especially in patients with acute kidney… 
Highly Cited
2012
Highly Cited
2012
Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice
Erythropoiesis-stimulating agents (ESA) are now central to the treatment of renal anemia and are associated with improved… 
2010
2010
Confirmatory analysis of continuous erythropoietin receptor activator and erythropoietin analogues in equine plasma by LC-MS for doping control.
Continuous erythropoietin receptor activator (CERA) is the third generation of recombinant human erythropoietin (rhEPO… 
2010
2010
Erythrocyte Indices in the Assessment of Iron Status in Dialysis-Dependent Patients with End-Stage Renal Disease on Continuous Erythropoietin Receptor Activator versus Epoetin β Therapy
Background: European guidelines stress that iron status should be regularly assessed for the optimal management of renal anemia… 
Highly Cited
2007
Highly Cited
2007
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
AIM This study was designed to assess the potential of the continuous erythropoietin receptor activator (C.E.R.A.) to correct… 
Highly Cited
2007
Highly Cited
2007
Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration*
ABSTRACT Aims: This Phase II study aimed to determine the optimal dose and administration schedule of continuous erythropoietin… 
Highly Cited
2007
Highly Cited
2007
The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury.
This study explored the tissue-protective properties of the continuous erythropoietin receptor activator (CERA) in an… 
2006
2006
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised…
This dose‐finding, open‐label study examined the potential of subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A… 
1991
1991
Matrix vesicle enzyme activity in endosteal bone following implantation of bonding and non-bonding implant materials.
The effect of bone bonding (KGy-Cera) and non-bone bonding (KGy-213) implant materials on primary mineralization was examined in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)